Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
clinical research/practice
costimulation
immunosuppressant - fusion proteins and monoclonal antibodies: belatacept
immunosuppressant - steroid
immunosuppression/immune modulation
immunosuppressive regimens - induction
immunosuppressive regimens - minimization/withdrawal
kidney transplantation/nephrology
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
12
07
2019
revised:
18
10
2019
accepted:
23
10
2019
pubmed:
5
11
2019
medline:
22
6
2021
entrez:
5
11
2019
Statut:
ppublish
Résumé
Simultaneous calcineurin inhibitor avoidance (CNIA) and early corticosteroid withdrawal (ESW) have not been achieved primarily due to excessive acute rejection. This trial compared 2 belatacept-based CNIA/ESW regimens with a tacrolimus-based ESW regimen. Kidney transplant recipients were randomized to receive alemtuzumab/belatacept, rabbit anti-thymocyte globulin (rATG)/belatacept, or rATG/tacrolimus. The combinatorial primary endpoint consisted of patient death, renal allograft loss, or a Modification of Diet in Renal Disease-calculated eGFR of <45 mL/min/1.73 m
Identifiants
pubmed: 31680394
doi: 10.1111/ajt.15688
pii: S1600-6135(22)22282-5
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Calcineurin Inhibitors
0
Immunosuppressive Agents
0
Abatacept
7D0YB67S97
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1055Subventions
Organisme : Bristol Myers Squibb
Pays : International
Investigateurs
Paul Brailey
(P)
Kelly Bruno
(K)
Janis Cicerchi
(J)
Ann Cline
(A)
Tonya Dorst
(T)
Mary Farnsworth
(M)
Deborah A Fernandez
(DA)
Alin Girnita
(A)
Jessi Lipscombe
(J)
Amanda Naciff-Stahl
(A)
Jennifer Rohan
(J)
Kristi Schneider
(K)
Alyssa Stucke
(A)
Jessica Thomas
(J)
Simon Tremblay
(S)
Informations de copyright
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Hibbs JLEJ, Alloway RR, Mogilishetty G, et al. Maintenance corticosteroid therapy is associated with an increased incidence of cardiovascular events in renal transplant recipients. Am J Transplant. 2009;9(Suppl 2):341.
Serrano OK, Kandaswamy R, Gillingham K, et al. Rapid discontinuation of prednisone in kidney transplant recipients: 15-year outcomes from the University of Minnesota. Transplantation. 2017;101:2590-2598.
Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4:1033-1041.
Tambur AR, Campbell P, Claas FH, et al. Sensitization in transplantation: assessment of risk (STAR) 2017 Working Group Meeting Report. Am J Transplant. 2018;18:1604-1614.
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564-577.
Humar ADT, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ. Steroid-free immunosuppression in kidney transplant recipients: the Minnesota experience. Clin Transplant. 2007;2007:43-50.
Haller MC, Royuela A, Nagler EV, Pascual J, Webster AC. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev. 2016:CD005632. https://doi.org/10.1002/14651858.CD005632.pub3.
Krisl JC, Alloway RR, Shield AR, et al. Acute rejection clinically defined phenotypes correlate with long-term renal allograft survival. Transplantation. 2015;99:2167-2173.
Prashar R, Venkat KK. Immunosuppression minimization and avoidance protocols: when less is not more. Adv Chronic Kidney Dis. 2016;23:295-300.
Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10:535-546.
Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10:547-557.
Kirk AD, Guasch A, Xu H, et al. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. Am J Transplant. 2014;14:1142-1151.
Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11:66-76.
Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-760.
Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med. 2016;374:333-343.
Bray RA, Gebel HM, Townsend R, et al. De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies. Am J Transplant. 2018;18:1783-1789.
Wekerle T. T cell subsets predicting belatacept-resistant rejection: finding the root where the trouble starts. Am J Transplant. 2017;17:2235-2237.
Betjes MG. Clinical consequences of circulating CD28-negative T cells for solid organ transplantation. Transpl Int. 2016;29:274-284.
Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013;43:2797-2809.
Mathews DVWW, Kim SC, Lowe MC, et al. Belatacept-resistant rejection is associated with CD28 + memory CD8 T cells. Am J Transplant. 2017;17:2285-2299.
Cortes-Cerisuelo MLS, Mathews DV, Winterberg PD, Larsen CP, Adams AB, Ford ML. Increased pretransplant frequency of CD28 + CD4 + TEM predicts belatacept-resistant rejection in human renal transplant recipients. Am J Transplant. 2017;17:2350-2362.
Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in lupus nephritis. Nature Immunol. 2019;20:902-914.
Castro-Rojas CM, Roskin KM, Moore CG, et al. Single cell analysis of kidney allograft rejection. Am J Transplant. 2019;19(Suppl 3):592.
Castro-Rojas CH, Salomonis N, Chetal K, Alloway RR, Woodle ES, Hildeman DA. Immediate post reperfusion in vivo transcriptional responses of human renal allograft populations to circulating anti-angiotensin II type 1 receptor antibody. Am J Transplant. 2019;19(Suppl 3):1067-1068.
Goring SM, Levy AR, Ghement I, et al. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients. Curr Med Res Opin. 2014;30:1473-1487.
Castro Rojas CM, Godarova A, Rike-Shields A, et al. Belatacept-refractory CD8 + CD28-CD38hi effector/memory T cells are targeted by mTOR inhibition leading to a preferential loss of CD40L. Am J Transplant. 2018;18(Suppl 4):958.
Heher E, Markmann JF. The clearer BENEFITS of belatacept. N Engl J Med. 2016;374:388-389.
Newell KA, Mehta AK, Larsen CP, et al. Lessons learned: early termination of a randomized trial of calcineurin inhibitor and corticosteroid avoidance using belatacept. Am J Transplant. 2017;17:2712-2719.
Mannon RSP, Mehta A, Ikle D, et al. Avoidance of CNI and steroids using belatacept- a preliminary report of CTOT-16. Am J Transplant. 2016;16(Suppl 3):401-402.